Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Cyclically Adjusted PB Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
96 GF Score
Price ¥39.38
GF Value ¥41.00
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio Related Terms


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.74 5.08 5.95 5.06 5.08

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 5.76 5.08 4.69 0.00

SHSE:600211 vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PB Ratio falls into.


SHSE:600211
96GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Tibet Rhodiola Pharmaceutical Holding Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.407/116.0564*116.0564
=12.407

Current CPI (Jun. 2026) = 116.0564.

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.188 102.400 2.480
201612 2.493 102.600 2.820
201703 2.189 103.200 2.462
201706 5.951 103.100 6.699
201709 6.018 104.100 6.709
201712 6.250 104.500 6.941
201803 6.305 105.300 6.949
201806 6.490 104.900 7.180
201809 6.972 106.600 7.590
201812 6.890 106.500 7.508
201903 7.024 107.700 7.569
201906 6.915 107.700 7.452
201909 7.396 109.800 7.817
201912 7.561 111.200 7.891
202003 8.034 112.300 8.303
202006 7.732 110.400 8.128
202009 7.872 111.700 8.179
202012 7.992 111.500 8.319
202103 8.513 112.662 8.770
202106 8.487 111.769 8.813
202109 8.876 112.215 9.180
202112 8.161 113.108 8.374
202203 8.689 114.335 8.820
202206 8.887 114.558 9.003
202209 9.636 115.339 9.696
202212 9.344 115.116 9.420
202303 10.374 115.116 10.459
202306 10.748 114.558 10.889
202309 10.608 115.339 10.674
202312 10.377 114.781 10.492
202403 11.353 115.227 11.435
202406 11.764 114.781 11.895
202409 11.262 115.785 11.288
202412 12.155 114.893 12.278
202503 12.724 115.116 12.828
202506 12.910 114.907 13.039
202509 11.018 115.471 11.074
202512 11.785 115.832 11.808
202603 12.100 116.303 12.074
202606 12.407 116.056 12.407

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥39.38 is trading 4% below its estimated GF Value™ of ¥41.00. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ¥41.00 vs. price of ¥39.38 (4% below fair value)
  • GF Score™: 96/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
96GF Score

Get the complete analysis for SHSE:600211

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.38
Price
¥41.00
GF Value